Last edition
News about "clinical-stage biotechnology company"
Immunomic Therapeutics Doses First Patient in Phase 1 Trial of Japanese Cedar Allergy Vaccine
Immunomic Therapeutics has initiated Phase 1 clinical testing of ITI-9001 after dosing the first participant in Japan, advancing the development of a next-generation therapeutic vaccine for Japanese cedar pollen allergy.
Clinical-stage Biotechnology Company | 06/07/2026 | By News Bureau
INTENT Biologics Secures FDA Breakthrough Therapy Tag for Diabetic Foot Ulcer Treatment Candidate
INTENT Biologics' PEP Biologic receives FDA Breakthrough Therapy designation for diabetic foot ulcers, accelerating development of its first-in-class exosome-based regenerative treatment aimed at improving healing outcomes in chronic wounds.
Clinical-stage Biotechnology Company | 03/07/2026 | By News Bureau | 167
Aplagon Doses First Patient in Phase IIa Trial of APAC for Chronic Limb-Threatening Ischemia
Aplagon has dosed the first patient in its Phase IIa HEALING trial evaluating APAC therapy for Chronic Limb?Threatening Ischemia caused by Peripheral Arterial Occlusive Disease in Finland.
Clinical-stage Biotechnology Company | 16/03/2026 | By News Bureau | 131
TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.
Clinical-stage Biotechnology Company | 09/03/2026 | By News Bureau | 226
Seaport Therapeutics receives up to USD 15 million from ARPA-H to develop GlyphCele, a lymphatic-targeted oral therapy designed to treat metabolic disease and pancreatic cancer by restoring gut lymphatic function.
Clinical-stage Biotechnology Company | 06/03/2026 | By News Bureau | 198
Diakonos Oncology Phase II Glioblastoma Trial Cleared to Continue After DSMB Safety Review
Independent safety review clears Diakonos Oncology’s Phase II DOC1021 glioblastoma trial to proceed, with no safety concerns identified to date.
Clinical-stage Biotechnology Company | 18/02/2026 | By News Bureau | 199
FDA Grants Orphan Drug Status to HanchorBio's HCB101 for Gastric Cancer
The Orphan Drug Status designation to HanchorBio supports development of next-generation CD47–SIRPα immunotherapy for advanced gastric adenocarcinoma across HER2-positive and HER2-negative subtypes.
Clinical-stage Biotechnology Company | 16/02/2026 | By News Bureau | 147
MerryLife Biomedical Reports Positive Phase I Data for Oral Alzheimer's Therapy TML-6
MerryLife Biomedical’s investigational oral therapy TML-6 demonstrated favourable safety and tolerability in Phase I, paving the way for a 210-patient global Phase II trial in early Alzheimer’s disease.
Clinical-stage Biotechnology Company | 10/02/2026 | By News Bureau | 132
Delonix Bioworks Secures NMPA IND Clearance for MenB Vaccine Candidate DX-104
China grants IND approval for DX-104 after Australia CTN clearance, paving the way for Phase I trials of Delonix’s engineered Group B meningococcal vaccine.
Clinical-stage Biotechnology Company | 09/02/2026 | By News Bureau | 255
Trace Biosciences Secures FDA IND Clearance for First Nerve-Specific Fluorescent Imaging Agent
FDA clears IND application for LGW16-03, enabling Trace Biosciences to begin first-in-human trials of its nerve-targeted imaging agent designed to reduce accidental nerve injuries during surgery.
Clinical-stage Biotechnology Company | 02/02/2026 | By News Bureau | 263
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy